碧生源(00926.HK)擬3199萬元受讓雪櫻花100%股權
格隆匯 2 月 1日丨碧生源(00926.HK)公佈,於2021年2月1日,公司間接全資附屬公司千瑞萬福與雪櫻花、管理人訂立重整投資協議,據此,千瑞萬福同意支付投資款人民幣3199萬元,並受讓雪櫻花100%股權。重整投資事項完成後,雪櫻花將成為公司間接全資附屬公司。
投資款將被管理人用於支付雪櫻花的破產費用、共益債務及根據重整計劃清償經法院認定的已申報債權。前述破產費用、共益債務及經法院認定的已申報債權的支付金額以投資款為上限,雪櫻花對超過投資款部分(如有)不承擔任何清償責任。此外,重整計劃執行完畢後,對於(i)按照重整計劃減免的債務;及(ii)未按規定申報的債權,雪櫻花不再承擔任何清償責任。
據悉,雪櫻花為一家於2005年於中國註冊成立的有限責任公司,其註冊資本為人民幣3000萬元,法定代表人于振豔。雪櫻花主要從事軟膠囊劑、顆粒劑、片劑、硬膠囊劑(含中藥前處理及提取)、精神藥品(阿普唑侖片)、雪櫻花牌氨基酸螯合鈣軟膠囊、蜂膠大蒜油軟膠囊、大豆異黃酮軟膠囊、藿香紫蘇軟膠囊的生產和銷售,於公吿日期,雪櫻花擁有15,570.61平米的生產車間、倉庫、辦公樓及配套建築,同時擁有53個藥品批件。
公吿稱,通過多年於非處方市場的營運,集團已豐富其經驗並累積足夠客户資源,並有意藉助其線上線下銷售藥品和保健品的成熟營銷渠道和營銷經驗。通過投資雪櫻花,集團可以擴充產品線(尤其是軟膠囊、片劑及硬膠囊藥品的生產),增強集團的營銷活力及規模效益。
集團可透過重整投資事項逐漸達成其於製藥、保健產品及大健康產業的整體佈局。重整投資事項將促使集團於製藥研發、生產方面取得更全面的資質,亦為集團於醫藥領域的全面佈局及發展奠下良好基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.